InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Cogent Biosciences, Inc.

COGT Clue Score18
United States Fiscal year ends December CIK 0001622229
$31.00 +3.06% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $31.00 +279.90% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 29 Mar 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Revenue8.4Operating income−26.2Net income−25.5Fiscal year 2018Revenue9.7 +16.4%Operating income−36.0Net income−34.5Fiscal year 2019Revenue22.5 +131.1%Operating income−32.2Net income−31.8Fiscal year 2020Revenue7.9 −65.0%Operating income−82.2Net income−74.8Fiscal year 2021Operating income−75.6Net income−72.3EPS, diluted−1.87Fiscal year 2022Operating income−147.8Net income−140.2EPS, diluted−1.73Fiscal year 2023Operating income−208.1Net income−192.4EPS, diluted−1.94Fiscal year 2024Operating income−275.9Net income−255.9EPS, diluted−1.94Fiscal year 2025Operating income−333.4Net income−328.9EPS, diluted−2.16
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 8.4 9.7 22.5 7.9 n/a n/a n/a n/a n/a
Growth +16.4% +131.1% −65.0%
Operating income −26.2 −36.0 −32.2 −82.2 −75.6 −147.8 −208.1 −275.9 −333.4
Net income −25.5 −34.5 −31.8 −74.8 −72.3 −140.2 −192.4 −255.9 −328.9
Growth
EPS, diluted n/a n/a n/a n/a −1.87 −1.73 −1.94 −1.94 −2.16

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2017Operating margin−312.8%Net margin−304.9%Free cash flow margin−319.9%Fiscal year 2018Operating margin−369.9%Net margin−354.8%Free cash flow margin−339.4%Fiscal year 2019Operating margin−143.0%Net margin−141.5%Free cash flow margin−184.7%Fiscal year 2020Operating margin−1,044.3%Net margin−950.4%Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Fiscal year 2025
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −312.8% −369.9% −143.0% −1,044.3% n/a n/a n/a n/a n/a
Net margin −304.9% −354.8% −141.5% −950.4% n/a n/a n/a n/a n/a
Free cash flow margin −319.9% −339.4% −184.7% n/a n/a n/a n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−25.8Capital expenditure−0.9Free cash flow−26.7Fiscal year 2018Operating cash flow−32.5Capital expenditure−0.5Free cash flow−33.0Fiscal year 2019Operating cash flow−41.5Capital expenditure−0.0Free cash flow−41.5Fiscal year 2020Operating cash flow−35.9Fiscal year 2021Operating cash flow−58.8Capital expenditure−1.7Free cash flow−60.5Fiscal year 2022Operating cash flow−118.6Capital expenditure−6.9Free cash flow−125.5Fiscal year 2023Operating cash flow−153.6Capital expenditure−2.8Free cash flow−156.4Fiscal year 2024Operating cash flow−207.8Capital expenditure−0.6Free cash flow−208.4Fiscal year 2025Operating cash flow−264.4Capital expenditure−1.6Free cash flow−266.0
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −25.8 −32.5 −41.5 −35.9 −58.8 −118.6 −153.6 −207.8 −264.4
Capital expenditure −0.9 −0.5 −0.0 n/a −1.7 −6.9 −2.8 −0.6 −1.6
Free cash flow −26.7 −33.0 −41.5 n/a −60.5 −125.5 −156.4 −208.4 −266.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2017Cash28.3Shareholders’ equity−48.8Fiscal year 2018Cash55.7Shareholders’ equity60.2Fiscal year 2019Cash37.4Shareholders’ equity31.8Fiscal year 2020Cash242.2Shareholders’ equity234.7Fiscal year 2021Cash219.7Shareholders’ equity214.2Fiscal year 2022Cash139.9Shareholders’ equity255.7Fiscal year 2023Cash53.2Shareholders’ equity257.8Fiscal year 2024Cash98.2Total debt0.0Net cash (debt)98.2Shareholders’ equity256.3Debt to equity0.00Fiscal year 2025Cash312.0Total debt222.9Net cash (debt)89.1Shareholders’ equity636.4Debt to equity0.35
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 28.3 55.7 37.4 242.2 219.7 139.9 53.2 98.2 312.0
Total debt n/a n/a n/a n/a n/a n/a n/a 0.0 222.9
Net cash (debt) n/a n/a n/a n/a n/a n/a n/a 98.2 89.1
Shareholders’ equity −48.8 60.2 31.8 234.7 214.2 255.7 257.8 256.3 636.4
Debt to equity n/a n/a n/a n/a n/a n/a n/a 0.00 0.35

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−25.8 −32.5 −41.5 −35.9 −58.8 −118.6 −153.6 −207.8 −264.4
Growth
Investment
−0.9 −0.5 −0.0 n/a −1.7 −6.9 −2.8 −0.6 −1.6
calc −26.7 −33.0 −41.5 n/a −60.5 −125.5 −156.4 −208.4 −266.0
Growth
calc n/a n/a n/a n/a −1.56 −2.14 −1.96 −2.01 −2.06
13.6 −10.5 23.2 8.4 −1.7 −124.7 −97.8 38.3 −399.5
Financing
−0.7 70.3 0.1 232.2 38.0 163.6 163.5 214.5 878.2

† The diluted share count jumps at 2022, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.